本篇文章7157字，读完约18分钟
For a long time, cancer was seen as an incurable disease that claimed countless lives. To overcome cancer, the human race has gone through a long process of exploration and improvement.
In the past hundred years, cancer treatments have made globally great progress and breakthrough in technology and method. A variety of tumor treatment methods have been developed at home and abroad, including the surgery, chemotherapy, radiotherapy and immunotherapy that is the main treatment methods. On the other hand, cancer incidence and mortality rates are rising continuesly and people are still expecting more effective anti tumor drugs and treatments.
Immunotherapy is the most promising way to conquer cancer
For the past decade, tumor immunotherapy has been considered the most promising way to conquer cancer. In 2013, the journal Science listed cancer immunotherapy as one of the top 10 scientific breakthroughs. Cancer immunotherapy is bringing new hope to millions of cancer patients
From PD-L1 to CAR-T therapy, advances in tumor immunology is changing the treat methods of many cancers and even rewriting the paradigm of anti tumor drugs development.The number of drugs in the pipeline is growing at an unprecedented rate, many large scale and innovative biotech companies are entering the cancer immunotherapy field.
Tumor immunotherapy works by enhancing the immune system's ability to target and kill tumor cells. At present, studies at home and abroad mainly involve the following directions: antibodies that block the inhibitory immune checkpoint pathway, such as PD1,PDL1,CTLA4 antibodies, etc.; Cell therapies based on dendritic cells and engineered T cells, such as CAR-T therapy; Vaccines that trigger antigen-specific immune responses in tumors; oncolytic carrier platform with oncolytic virus or oncolytic bacteria.
In recent years, the emerging oncolytic virus therapy has attracted wide attention in the medical market and has attracted many domestic and foreign manufacturers to layout the oncolytic virus pipelines, gradually forms a fierce competition pattern. At the same time, an even more cutting-edge approach to tumor immunotherapy -- oncolytic bacteria therapy -- is starting to emerge in the mainstream biomedical market
YB1 -- the first oncolytic bacterial carrier in the world
YB1 is an innovative tumor-targeting drug developed by HKND YB1 PHARMACEUTUCAL LIMITED. By modifying Salmonella, it can be used as a carrier of tumor drugs with stronger targeting ability.In the field of tumor immunotherapy, YB1 is the world's first oncolytic bacterial carrier. This cutting-edge technology is great significance in promoting the innovation and development of cancer immunotherapy technology worldwide and is an exciting news for patients and the industry.
HKND YB1 PHARMACEUTUCAL LIMITED. focuses on the research and development of innovative drugs in the field of tumor targeted therapy, owns the world's leading oncolytic bacteria technology platform based on synthetic biology with independent intellectual property rights, and is committed to providing revolutionary cancer immunotherapy solutions to the world.
Although oncolytic bacteria are just being mentioned in the biomedical market, YB1 oncolytic bacteria has been developed for many years. In 2011, the r&d team realized the highly efficient programming technology of salmonella-Red for the first time, which established the foundation of the synthetic biology transformation of salmonellae. After more than a decade of development, the core r&d team of HKND YB1 PHARMACEUTUCAL LIMITED. has successfully created a strain of Salmonella Typhimurium that has been genetically programmed to be tumor-lytic and has named it YB1.
It is worth mentioning that YB1 is also the first strain specially designed for tumors treatment 不by using synthetic biology technology. Besides oncolytic properties, it also has powerful drug-carrying capacity
Studies have shown that the oncolytic bacterium YB1, as a carrier, can efficiently deliver and carry drugs including antibodies, mRNA, protein drugs, oncolytic viruses, etc. to precisely target the hypoxic region in the tumor center and replicate and amplify in large quantities inside the tumor, thus increasing the concentration of YB1 in solid tumors. YB1 has great clinical application potential that could release a variety of therapeutic drugs inside the tumor to inhibit tumor growth and dissolve tumor as well as eliminate tumor metastasis
Tumor hypoxic specific targeting technology ensure safety and effectiveness
As an oncolytic bacteria, the biggest difficulty in the technology development of YB1 lies in how to ensure safety and achieve targeting. This is the same problem, because achieving targeting also means improving security. YB1 is the world's first tumor hypoxic specific targeting technology to achieve the safety ,targeting and effectiveness .
The characteristics of solid tumor microenvironment are the basis of YB1's application of hypoxic-specific targeting techniques: there is a hypoxic area in the center of the tumor with an oxygen concentration of less than 0.5%, which is significantly different from normal organs with an oxygen concentration of 1-5%. The hypoxia characteristic of the tumor is obvious. If the facultation-anaerobic salmonella can survive only at an oxygen content of less than 0.5%, it can target the tumor and avoid damage to normal tissues -- this is the principle of YB1 technology.
（YB1Design concept drawing）
Because salmonella has strong inhibitory effect on tumor growth and help aggregation of tumor , but has damage to normal tissues. HKND YB1 PHARMACEUTUCAL LIMITED. then through synthetic biology to transform salmonella, the modified salmonella YB1 in high oxygen content (> 0.5%) would spontaneously lyse and die without harming normal organs. In low oxygen conditions (<0.5%) rapidly proliferate and release the carrying antitumor drugs to attack the tumor to achieve tumour-specific hoarding and aggression
Through oxygen regulation,YB1 achieves precise tumor targeting. When the oxygen content in the body is less than 0.5%, its ability to accumulate in the tumor is not affected and can reach 10^9CFU/g. However, if YB1 is exposed to the environment with oxygen content higher than 0.5%, such as liver,YB1 will be quickly cleared to protect normal organs from drug damage.
YB1 has already completed a series of pet cancer clinical trials and obtains successful treatment effect. The R&D team has selected various tumor types and effective treatments on the pet dog primary cancer clinical treatment. The efficient and safety has been sufficiently demonstrated that provides strong evidence and base for the next step in the YB1 human clinical trials research.
HKND YB1 PHARMACEUTUCAL LIMITED. has laid out a number of product pipelines for YB1 technology. Currently, the company is fully promoting the process research of YB1-TOX pipeline. Based on the information obtained from the pet dog primary cancer clinical treatment, the company will carry out clinical research on sarcoma and melanoma firstly and sincerely hope to benefit for the cancer patients all over the world in future.
